Carlo Albera Selected Research

pirfenidone

9/2021	Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective.
3/2019	Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis.
3/2019	The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone.
1/2019	Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis.
1/2019	Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
1/2019	Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis.
10/2018	Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study.
1/2018	Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trials.
12/2017	Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.
1/2017	An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carlo Albera Research Topics

Disease

23	Idiopathic Pulmonary Fibrosis 01/2020 - 07/2009
5	Disease Progression 01/2021 - 01/2016
3	Interstitial Lung Diseases (Interstitial Lung Disease) 07/2021 - 01/2014
3	Dyspnea (Shortness of Breath) 01/2019 - 01/2016
2	Fibrosis (Cirrhosis) 09/2021 - 01/2020
2	Infections 01/2020 - 02/2019
2	Nausea 01/2016 - 05/2011
2	Headache (Headaches) 01/2016 - 01/2016
2	Fatigue 01/2016 - 07/2009
2	Pulmonary Arterial Hypertension 03/2015 - 01/2015
2	Sarcoidosis (Schaumann Disease) 11/2014 - 10/2006
1	Pulmonary Hypertension 10/2022
1	Asthma (Bronchial Asthma) 01/2022
1	Reperfusion Injury 01/2022
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2022
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2022
1	Cough 01/2022
1	Pain (Aches) 07/2021
1	Inborn Genetic Diseases (Disease, Hereditary) 02/2019
1	Cystic Fibrosis (Mucoviscidosis) 02/2019
1	Respiratory Insufficiency (Respiratory Failure) 02/2019
1	Angiomyolipoma 01/2018
1	Intervertebral Disc Displacement (Herniated Disc) 01/2016
1	Lung Neoplasms (Lung Cancer) 01/2016
1	Hypertension (High Blood Pressure) 01/2016
1	Contusions 01/2016
1	Aortic Aneurysm (Aneurysm, Aortic) 01/2016
1	Thalassemia 01/2015
1	Granuloma 11/2014
1	Necrosis 11/2014
1	Pulmonary Sarcoidosis 11/2014
1	Mesothelioma 06/2014
1	Malignant Mesothelioma 06/2014
1	Neoplasms (Cancer) 06/2014
1	Glomerulonephritis 01/2014
1	Lung Diseases (Lung Disease) 01/2014
1	Relapsing-Remitting Multiple Sclerosis 01/2014
1	Dizziness (Lightheadedness) 05/2011
1	Exanthema (Rash) 05/2011
1	Dyspepsia (Indigestion) 05/2011
1	Vomiting 05/2011
1	Anorexia 05/2011
1	Chills 07/2009
1	Fever (Fevers) 07/2009
1	Human Influenza (Influenza) 07/2009

Drug/Important Bio-Agent (IBA)

21	pirfenidoneIBA 09/2021 - 05/2011
2	nintedanibIBA 01/2022 - 09/2021
2	Acetylcysteine (Siran)FDA LinkGeneric 01/2017 - 01/2016
2	Biomarkers (Surrogate Marker)IBA 03/2015 - 06/2014
2	Pharmaceutical PreparationsIBA 05/2011 - 07/2009
1	SolutionsIBA 10/2022
1	Biological ProductsIBA 01/2022
1	Cell-Free Nucleic AcidsIBA 01/2022
1	C-Reactive ProteinIBA 01/2022
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 01/2022
1	Everolimus FDA Link 01/2021
1	Connective Tissue Growth FactorIBA 01/2020
1	pamrevlumabIBA 01/2020
1	Monoclonal AntibodiesIBA 01/2020
1	EnzymesIBA 01/2020
1	Glycoproteins (Glycoprotein)IBA 01/2020
1	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 02/2019
1	Tamoxifen FDA LinkGeneric 01/2018
1	Metalloproteases (Metalloproteinases)IBA 01/2018
1	Messenger RNA (mRNA)IBA 01/2018
1	Ustekinumab (CNTO 1275)FDA Link 11/2014
1	Interleukin-23 (Interleukin 23)IBA 11/2014
1	golimumab FDA Link 11/2014
1	CytokinesIBA 11/2014
1	InterleukinsIBA 11/2014
1	Caveolin 1IBA 06/2014
1	Interferon-betaIBA 01/2014
1	interferon gamma-1b FDA Link 07/2009
1	Infliximab (Remicade)FDA Link 10/2006
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2006

Therapy/Procedure

8	Therapeutics 01/2022 - 10/2006
1	Biological Therapy 01/2022
1	Transplantation 01/2022
1	Length of Stay 07/2021
1	Artificial Respiration (Mechanical Ventilation) 07/2021
1	Intravenous Infusions 01/2020
1	Lung Transplantation 01/2020
1	Endarterectomy (Thromboendarterectomy) 01/2015